Company profile
Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| INETAGUGENE GEPERPAVEC | phase2 | — | 2 | unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04917874 | phase3 | completed | 2021-05-25 | 2023-07-31 | Krystal Biotech, Inc. | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa |
| NCT04540900 | phase1 | active_not_recruiting | 2020-10-07 | 2024-10-16 | Krystal Biotech, Inc. | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions |
| NCT03536143 | phase1_2 | completed | 2018-05-06 | 2019-11-01 | Krystal Biotech, Inc. | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients |
| NCT06724900 | phase1_2 | active_not_recruiting | 2024-11-20 | 2025-07-01 | Krystal Biotech, Inc. | A Study Assessing KB304 for the Treatment of Wrinkles in Women |
| NCT05504837 | phase1 | recruiting | 2023-06-30 | 2026-12-01 | Krystal Biotech, Inc. | A Study Assessing KB407 for the Treatment of Cystic Fibrosis |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125774 | BLA | Krystal Biotech, Inc. | ||||
Loading… | ||||||